Cumulus Neuroscience secures £3.3m to scale its commercial team and marketing operations.
The investment was led by Whiterock with participation from regional funds and angel backers.
Cumulus Neuroscience develops digital biomarker platforms and dry sensor EEG headsets to advance neuroscience clinical trials and patient care.
Cumulus Neuroscience has secured £3.3m in a funding round led by Whiterock, which contributed £1.5m through its Growth Capital Fund. Additional backing came from the Investment Fund for Northern Ireland via Clarendon Fund Managers with £1.3m, alongside £0.3m from ACF Investors and £0.2m from Co Fund NI. The capital will be directed towards marketing initiatives and expanding the commercialisation team, including senior appointments in business development and B2B marketing.
The company operates out of Belfast and Dublin, utilising its NeuLogiq platform and dry sensor EEG headsets to capture objective brain function data. This technology supports biopharmaceutical partners in conducting clinical trials for conditions such as Alzheimer's and depression by enabling frequent assessments both in clinical settings and remotely.
From the founder
"There is a substantial unmet need today in neuroscience clinical studies. Many study endpoints are measured with traditional pen and paper assessments which lack objective data about brain function. Biopharma companies need objective data to effectively establish baseline information about whether a drug is engaging with the region of the brain that a particular drug is targeting, whether a drug is effective, and informing which cohort of patients may benefit the most from a particular drug."
Tina Sampath
Chief Executive at Cumulus Neuroscience
Investor perspective
"We are excited to have led this investment round to help fuel the next phase of growth for Cumulus with an equity investment from Whiterock’s Growth Capital Fund. We look forward to partnering with Tina and the Executive team as they deploy their groundbreaking technology and data analytics tools into projects alongside some of the world’s leading pharma and biotech companies"
David McCurley
Investment Director, Whiterock
Use of funds
- 01Invest in sales and marketing
Investors
Categories
About the company
Cumulus Neuroscience
Digital biomarker platform provider for neuroscience clinical trials and patient monitoring.